Overview

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Status:
Active, not recruiting
Trial end date:
2021-12-17
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than [<] 12 years) with inadequately controlled partial onset seizures (POS) or primary generalized tonic clonic (PGTC) seizures.
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Inc.